A. Monnier

发表

Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: Evidence from a pooled analysis of 2,838 patients randomized in 7 trials

M. Buyse, V. Georgoulias, F. Fossella, 2008 .

Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.

J. Bonneterre, A. Monnier, I. van Praagh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer

A. Monnier, 2007, Expert review of anticancer therapy.

Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial

M. Namer, J. Bonneterre, A. Monnier, 2007, British Journal of Cancer.

Adjuvant trials: Aromatase inhibitors in early breast cancer--are they alike?

A. Monnier, 2006, Cancer treatment reviews.

The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98.

A. Monnier, 2006, Breast.

FACE: the barefaced facts of AI potency

A. Monnier, 2010, Cancer management and research.

Refining the postmenopausal breast cancer treatment paradigm: the FACE trial

A. Monnier, 2006, Expert review of anticancer therapy.

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

T. Delozier, J. Bonneterre, B. Asselain, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.

M. Namer, J. Bonneterre, A. Monnier, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.

A. Monnier, J. Buentzel, O. Micke, 2006, International journal of radiation oncology, biology, physics.

Assessment of care by breast cancer patients participating or not participating in a randomized controlled trial: a report with the Patients' Committee for Clinical Trials of the Ligue Nationale Contre le Cancer.

A. Monnier, C. Tarpin, F. Dalenc, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of vinorelbine in patients with androgen-independent prostate cancer.

M. Piccart, D. Chopin, Y. Humblet, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.

J. Pujol, A. Monnier, J. Douillard, 1994, Seminars in oncology.

Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

P. Neven, G. von Minckwitz, A. Monnier, 2008, Cancer.

Decision-making and breast cancer clinical trials: how experience challenges attitudes.

A. Monnier, J. Mancini, C. Tarpin, 2007, Contemporary clinical trials.

Effects of adjuvant aromatase inhibitor therapy on lipid profiles

A. Monnier, 2006, Expert review of anticancer therapy.

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.

T. Delozier, M. Namer, A. Monnier, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of radiation±Ethyol® (Amifostine) in patients with head and neck cancer

D. Brizel, A. Monnier, F. Eschwège, 1997 .

A longitudinal analysis of patient satisfaction with care and quality of life in ambulatory oncology based on the OUT-PATSAT35 questionnaire

J. Bosset, A. Monnier, A. Brédart, 2014, BMC Cancer.

Phase II Study of Oral Idarubicin in Elderly Patients with Advanced Breast Cancer

M. Namer, M. Marty, A. Monnier, 1990, American journal of clinical oncology.

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

G. Hortobagyi, R. Rizzoli, F. Saad, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients

P. Hérait, A. Monnier, J. Robert, 2004, Cancer Chemotherapy and Pharmacology.

Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer.

L. Mauriac, J. Canon, G. Romieu, 2009 .

Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer

T. Delozier, A. Monnier, E. Gamelin, 2003, British Journal of Cancer.

Determinants of patient satisfaction in ambulatory oncology: a cross sectional study based on the OUT-PATSAT35 questionnaire

J. Bosset, A. Monnier, A. Brédart, 2011, BMC Cancer.

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.

A. Monnier, P. Fumoleau, E. Pujade-Lauraine, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].

M. Espié, X. Pivot, J. Pierga, 2012, Bulletin du cancer.

Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review

A. Monnier, 2009, Therapeutics and clinical risk management.

Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.

N. Ibrahim, A. Monnier, J. Douillard, 1998, European journal of cancer.

Original Paper Docetaxel (Taxotere 1 ) Plus Cisplatin: an Active and Well-tolerated Combination in Patients with Advanced Non-small Cell Lung Cancer

N. Ibrahim, A. Monnier, T. Chevalier, 1998 .

[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].

L. Mauriac, M. Tubiana-Hulin, A. Monnier, 2001, Bulletin du cancer.

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.

P Chomy, J L Pujol, J. Pujol, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.

D. Brizel, A. Monnier, F. Eschwège, 2005, International journal of radiation oncology, biology, physics.

Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials.

M. Namer, J. Bonneterre, M. Campone, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma

R. Crevoisier, J. Bourhis, V. Georgoulias, 2001 .

Prognostic factors of contralateral breast cancer (CBC) in 3,653 early breast cancer (EBC) patients (pts): 9-year follow-up results of French Adjuvant Study Group (FASG) trials.

M. Namer, J. Bonneterre, A. Monnier, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.

S. Schraub, M. Namer, J. Bonneterre, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.

R. James, J. Zalcberg, M. Millward, 1999, Seminars in oncology.

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.

D. Brizel, A. Monnier, F. Eschwège, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.

C. Boni, H. Mouridsen, A. Monnier, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I-II trial of Seraspenide (AcSDKP): a supressor of myelopoiesis protects against chemotherapy myelotoxicity (version 10 february 1993)

A. Vekhoff, C. Chastang, D. Khayat, 1994 .

Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.

D. Caillaud, D. Spaeth, A. Monnier, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.

J. Pujol, A. Monnier, J. Douillard, 1994, British Journal of Cancer.

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study

A. Monnier, J. Douillard, X. Sun, 2001, British Journal of Cancer.

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

C. Boni, H. Mouridsen, F. Jänicke, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.

J. Bonneterre, A. Monnier, P. Fumoleau, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.

C. Chastang, A. Monnier, Y. Chrétien, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.

S. Schraub, M. Namer, A. Monnier, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation properties of the French version of the OUT-PATSAT35 satisfaction with care questionnaire according to classical and item response theory analyses

J. Bosset, A. Monnier, J. Hardouin, 2014, Quality of Life Research.

Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node‐positive, early‐stage, invasive breast carcinoma undergoing breast‐conserving surgery

A. Courdi, A. Monnier, D. Berton‐Rigaud, 2005, Cancer.

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

M. Namer, J. Bonneterre, A. Monnier, 2002, British Journal of Cancer.

Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.

M. Espié, A. Monnier, M. Marty, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I II R andomized T rial o f A mifostine a s a Radioprotector i n H ead a nd N eck C ancer

D. Brizel, A. Monnier, F. Eschwège, 2000 .

Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of Seven Randomized Clinical Trials

V. Georgoulias, F. Fossella, S. Laporte, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences

R. Gelber, A. Goldhirsch, A. Coates, 2014, Breast Cancer Research and Treatment.

1096 Preliminary report of a phase II study of docetaxel (taxotere® and cisplatin in advanced non small cell lung cancer (NSCLC)

N. Ibrahim, A. Monnier, J. Douillard, 1995 .

Pirarubicin in advanced breast cancer: a French cooperative phase II study.

T. Delozier, M. Namer, A. Monnier, 1990, European journal of cancer.

6 Final report of a phase III randomized trial of amifostine as a radioprotectant in head and neck cancer

D. Brizel, A. Monnier, F. Eschwège, 1999 .

Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer.

A. Monnier, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Postmenopausal Patients with Node-Positive Resectable Breast Cancer

M. Héry, M. Namer, A. Monnier, 2012, Drugs.

Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.

M. Namer, J. Bonneterre, M. Campone, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Rurality and survival differences in lung cancer: a large population-based multivariate analysis.

J. Dalphin, A. Monnier, V. Westeel, 2008, Lung cancer.

Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study)

P. Neven, A. Monnier, R. Coleman, 2006 .

P105 Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer

P. Neven, A. Monnier, N. Bundred, 2005 .

A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer.

E. Lemarié, B. Milleron, A. Monnier, 2000, European journal of cancer.

[Ductal carcinoma in situ: role of the boost].

I. Barillot, P. Maingon, A. Monnier, 2008, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Does time interval between surgery and adjuvant chemotherapy initiation modify treatment efficacy in operable, breast cancer patients? French Adjuvant Study Group (FASG) results

M. Namer, J. Bonneterre, A. Monnier, 2005 .

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

D. Amadori, S. Fosså, A. Haese*, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.

A. Monnier, P. Fumoleau, N. Colombo, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

D. Amadori, S. Fosså, C. Parker, 2011 .

Determinants of patient satisfaction in ambulatory oncology: a cross sectional study based on the OUT-PATSAT35 questionnaire

J. Bosset, A. Monnier, A. Brédart, 2011, BMC Cancer.

DETERMINANTS OF SATISFACTION WITH CARE IN CANCER OUTPATIENTS: A PROSPECTIVE STUDY BASED ON THE EORTC OUT-PATSAT35 QUESTIONNAIRE

J. Bosset, A. Monnier, M. Mercier, 2009 .

Phase II study with Taxol® (paclitaxel) and Gemzar® (gemcitabine) in metastatic non-small cell lung cancer (NSCLC)

A. Monnier, J. Douillard, X. Sun, 2000 .

A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients

P. Hérait, A. Monnier, J. Robert, 2004, Cancer Chemotherapy and Pharmacology.

Comparison of docetaxel and vinca alkaloid, alone or in combination with other chemotherapy agents, in the first-line treatment of advanced non-small cell lung cancer (NSCLC): A meta-analysis.

V. Georgoulias, S. Laporte, J. Pujol, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

P. Neven, G. von Minckwitz, A. Monnier, 2008, Cancer.

Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.

M. Espié, A. Monnier, M. Marty, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III randomized double blind placebo controlled trial of carboplatin and radiation therapy ± amifostine in patients with head and neck cancer

N. Willich, A. Monnier, J. Buentzel, 2001 .